Fayuvi is authorized for pediatric patients with preserved neurodevelopmental function following a study comparing treated ...

How direct T-cell reprogramming could simplify CAR-T manufacturing, expand patient access, and extend cellular immunotherapy ...

CCRM CEO Michael May on quantum computing, commercialization, and the next era of cell therapy What was your biggest professional highlight of the past 12 months?

Discover how the right excipient can support efficient processing, reliable dosing, fast dissolution and a more patient-friendly experience, and learn what galenIQ™ brings to modern sachet development ...

Novartis and Bristol Myers Squibb have paused clinical trials of their respective CD19-directed CAR T therapies in autoimmune diseases while they review safety data. Novartis halted eight studies of ...

Scientists are already using AI in the lab – but many are doing so without the safeguards their employers may assume are in place ...

As demand for GLP-1 medicines grows, injectable manufacturers must increase output without compromising quality or squeezing supply for other therapies ...

Patients own immune cells genetically modified in the laboratory, track down the disease driving B cells, even deep within tissues. Inflammatory foci such as those seen here around the knee joints of ...

What was your biggest professional highlight of the past 12 months? We’ve seen several notable highlights over the past 18 months, but if I had to name one, it would be the approval of lisaftoclax in ...

A distinct population of CAR T cells could help predict whether products containing fewer cells than intended will still produce a therapeutic response, according to a new study. Researchers from the ...

IBTV speaks with industry leaders at ASGCT 2026 about the technologies, processes, and manufacturing strategies helping advanced therapies progress toward commercial scale ...

All 16 patients treated with an individualized cancer vaccine after surgery for locally advanced head and neck cancer remained disease-free after a median follow-up of 41 months, according to updated ...